Oculis' OCS-01 Fails Phase 3 DIAMOND Trials for Diabetic Macular Edema; FDA Filing Abandoned
OCS is trading near its 52-week low of $16 (11% below the low) on elevated volume (6.7× avg).
Summary
Oculis' OCS-01 drug failed to meet its primary efficacy endpoint in Phase 3 trials for diabetic macular edema, leading the company to abandon FDA filing plans for this indication and re-prioritize its pipeline.
Key Events · Product Development and Regulatory · OCS
-
OCS-01 Phase 3 Failure
The OCS-01 eye drops did not meet the primary endpoint of improved best corrected visual acuity (BCVA) in two Phase 3 DIAMOND trials for diabetic macular edema (DME).
-
FDA Filing Abandoned
Oculis will not pursue an FDA regulatory filing for OCS-01 in DME following the trial results.
-
Pipeline Re-prioritization
The company will shift its development focus and financial resources to its Privosegtor program for optic neuropathies and Licaminlimab for dry eye disease.
-
Strong Cash Runway
Oculis reported a strong cash position of $278 million as of March 31, 2026, providing a cash runway into the second half of 2029.
Analysis · OCS · Life Sciences
Oculis announced that its OCS-01 eye drops failed to meet the primary endpoint in two Phase 3 trials for diabetic macular edema (DME). This critical setback means the company will not pursue FDA approval for OCS-01 in this indication, leading to a significant re-evaluation of its pipeline and future revenue potential. The company will now pivot its focus to other late-stage programs, Privosegtor for optic neuropathies and Licaminlimab for dry eye disease, while leveraging its strong cash position.
At the time of this filing, OCS was trading at $14.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $16.00 to $34.48. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.